tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Vor Biopharma (VOR) and Eliem Therapeutics (ELYM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied Therapeutics (APLTResearch Report), Vor Biopharma (VORResearch Report) and Eliem Therapeutics (ELYMResearch Report) with bullish sentiments.

Applied Therapeutics (APLT)

In a report released yesterday, Brian Skorney from Robert W. Baird maintained a Buy rating on Applied Therapeutics, with a price target of $18.00. The company’s shares closed last Thursday at $2.42, close to its 52-week low of $1.45.

According to TipRanks.com, Skorney has 0 stars on 0-5 stars ranking scale with an average return of -4.0% and a 44.4% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

Applied Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.25.

See Insiders’ Hot Stocks on TipRanks >>

Vor Biopharma (VOR)

In a report issued on April 6, Jack Allen from Robert W. Baird maintained a Buy rating on Vor Biopharma, with a price target of $38.00. The company’s shares closed last Thursday at $6.28, close to its 52-week low of $5.65.

According to TipRanks.com, Allen is ranked 0 out of 5 stars with an average return of -19.6% and a 22.2% success rate. Allen covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Taysha Gene Therapies, and Decibel Therapeutics.

Currently, the analyst consensus on Vor Biopharma is a Strong Buy with an average price target of $33.20.

Eliem Therapeutics (ELYM)

Leerink Partners analyst Marc Goodman initiated coverage with a Buy rating on Eliem Therapeutics on April 6 and set a price target of $33.00. The company’s shares closed last Thursday at $8.40, close to its 52-week low of $7.97.

According to TipRanks.com, Goodman is a 4-star analyst with an average return of 4.1% and a 48.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Amylyx Pharmaceuticals Inc, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eliem Therapeutics with a $33.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on APLT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed